Matricelf gets FDA feedback for proposed NewRal spinal cord trial elements
FDA feedback supports Matricelf’s proposed patient population, single-arm open-label trial design, primary safety assessments and exploratory efficacy measures as it prepares for a future IND submission for NewRal.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.